Metafora Biosystems

Metafora Biosystems is a Paris-based diagnostics company leveraging a proprietary platform combining single-cell metabolism analysis with artificial intelligence. The company has achieved commercial and regulatory milestones, most notably the national coverage recommendation in France for its flagship IVD test, METAglut™, for diagnosing the rare neurological disorder Glut1 Deficiency Syndrome (Glut1DS). Backed by significant non-dilutive grants like the EIC Accelerator funding and strategic partnerships with diagnostic leaders, Metafora is positioned to expand its AI-powered cytometry platform into broader research and clinical applications in immunology and cell therapy.

Integrated platform combining proprietary single-cell metabolism profiling reagents with METAflow, an AI-powered 'augmented intelligence' software for cytometry data analysis.

In the niche of Glut1DS testing, METAglut™ appears to be a first-in-class blood-based diagnostic, competing against traditional, more invasive methods like lumbar puncture and genetic testing. In the broader AI cytometry analysis market, METAflow competes with software from instrument vendors (e.g., BD, Beckman Coulter, Standard BioTools) and independent bioinformatics companies. Its differentiation lies in its specific focus on metabolic profiling and 'augmented intelligence' for reproducible analysis.